Adrenomedullin: Complete Research Profile — The Vasoactive CGRP-Family Peptide in Cardiovascular, Tumor Biology, and Neuroendocrine Research (2026)

# Adrenomedullin: Complete Research Profile — The Vasoactive CGRP-Family Peptide in Cardiovascular, Tumor Biology, and Neuroendocrine Research (2026)

Adrenomedullin (AM) is a 52-amino-acid vasoactive peptide belonging to the calcitonin gene-related peptide (CGRP) superfamily. First isolated from human pheochromocytoma tissue in 1993, AM has since been established as a pleiotropic signaling molecule produced by virtually every major tissue in the body. Its discovery as a potent hypotensive agent opened a broad research program spanning cardiovascular biology, tumor angiogenesis, neuroprotection, sepsis biomarker development, and receptor pharmacology.

Unlike many bioregulatory peptides that operate in narrow physiological niches, adrenomedullin exerts effects across the cardiovascular, nervous, immune, and endocrine systems. Its unique receptor biology — mediated by heterodimeric complexes of the calcitonin receptor-like receptor (CLR/CRLR) with receptor activity-modifying proteins (RAMPs) — has established it as a flagship model for understanding how GPCRs achieve functional diversification. This combination of broad biology and pharmacologically tractable receptors makes AM a compelling target for mechanistic research across multiple disciplines.

> Research Use Only: All adrenomedullin research compounds are sold strictly for laboratory investigation. This profile is intended for researchers and does not constitute medical advice or clinical guidance.

---

What Is Adrenomedullin?

Adrenomedullin is encoded by the ADM gene and is synthesized as a 185-amino-acid preproadrenomedullin precursor. Enzymatic processing yields two biologically active fragments: the mature 52-amino-acid AM peptide and proadrenomedullin N-terminal 20 peptide (PAMP), which has its own vasodilatory activity. The mature AM sequence is C-terminally amidated — a post-translational modification essential for full biological activity — and contains an intramolecular disulfide bridge forming a six-amino-acid ring characteristic of the calcitonin superfamily.

Although originally named for the adrenal medulla where it was first identified, adrenomedullin is now recognized as a ubiquitously expressed peptide. Significant production sites include:

• •Vascular endothelium and smooth muscle — particularly important for autocrine/paracrine vascular tone regulation
• •Heart — cardiomyocytes and cardiac fibroblasts, with upregulation in hypertrophy and failure
• •Lung — the largest single site of AM clearance and production
• •Kidney — contributing to renal hemodynamics and electrolyte handling
• •Brain — hypothalamus, pituitary, and cerebrovascular endothelium
• •Gut — epithelial and enteroendocrine cells
• •Immune cells — macrophages and dendritic cells

Circulating AM is largely derived from endothelial cells and is rapidly cleared with a plasma half-life of approximately 22 minutes. Because of this short half-life, researchers typically measure the more stable midregional fragment, MR-proADM, as a surrogate for AM secretion in biomarker studies.

---

Receptor Biology: The CLR/RAMP System

The mechanism by which adrenomedullin signals through heterodimeric receptor complexes represents one of the most important paradigm shifts in GPCR pharmacology of the past three decades. Understanding this system is essential for interpreting AM research data.

CLR and RAMP2/3 Heterodimers

Adrenomedullin signals through the calcitonin receptor-like receptor (CLR, also called CRLR), a seven-transmembrane GPCR that requires co-expression with receptor activity-modifying proteins (RAMPs) for proper membrane trafficking and ligand specificity:

• •AM₁ receptor = CLR + RAMP2: The primary, high-affinity AM receptor subtype; predominantly expressed in vascular endothelium; essential for embryonic vascular development; responsible for most cardiovascular AM effects
• •AM₂ receptor = CLR + RAMP3: Lower affinity for AM; expressed in endothelium, heart, and various epithelia; exhibits distinct signaling bias from AM₁

The CGRP receptor (CLR + RAMP1) can also bind AM with lower affinity, creating cross-reactivity relevant to CGRP research. This ligand promiscuity within the CLR/RAMP system makes careful receptor subtype delineation critical in AM research. This receptor architecture was characterized in detail in a foundational study of cardiomyocyte AM signaling (PubMed 11754972).

Intracellular Signaling Cascades

Upon AM binding, CLR/RAMP2 activates Gαs, leading to:

1. cAMP/PKA pathway — the primary signaling axis; promotes vasodilation via smooth muscle relaxation and endothelial barrier enhancement

2. PI3K/Akt pathway — activates survival signaling; implicated in anti-apoptotic and pro-angiogenic effects in endothelial cells

3. cGMP/NO axis — AM stimulates nitric oxide synthase (eNOS) activation in endothelial cells, contributing to vasodilation via a cAMP-independent mechanism

4. β-arrestin-mediated signaling — RAMP identity influences biased agonism; RAMP2 and RAMP3 differ in their ability to recruit β-arrestins, creating distinct internalization and signaling profiles

This receptor pharmacology complexity means that the research context — cell type, receptor subtype expression, co-expressed RAMP — significantly shapes experimental outcomes.

---

Cardiovascular Research

The cardiovascular biology of adrenomedullin is the most extensively studied aspect of its biology. AM functions both as an endocrine hormone (acting on distant vascular beds) and as a local autocrine/paracrine regulator of vascular tone, permeability, and remodeling.

Vasodilation and Blood Pressure Regulation

AM is one of the most potent endogenous vasodilators identified. Its hypotensive effects are mediated through:

• •Activation of adenylyl cyclase in vascular smooth muscle, raising cAMP and activating PKA to reduce calcium sensitivity and promote smooth muscle relaxation
• •Endothelial NO release contributing additively to vasodilation
• •Inhibition of adrenergic vasoconstriction at the receptor level

Plasma AM concentrations rise significantly in hypertension, suggesting a counter-regulatory role. Genetically modified mouse models overexpressing AM show reduced blood pressure and protection against vascular remodeling, while AM knockout mice develop systemic and pulmonary hypertension. These gene-disruption models have been foundational for establishing AM's role as an endogenous antihypertensive signaling factor.

Endothelial Barrier Function and Vascular Permeability

Beyond vasodilation, AM is increasingly recognized as a critical regulator of endothelial barrier integrity. AM/CLR/RAMP2 signaling tightens endothelial junctions and reduces vascular permeability through:

• •Rac1-mediated cytoskeletal rearrangement strengthening cell-cell contacts
• •VE-cadherin stabilization at adherens junctions
• •Suppression of Rho kinase-dependent barrier disruption

This barrier-stabilizing activity has attracted significant attention in the context of sepsis-associated vascular leak and ARDS, where pathological hyperpermeability drives organ dysfunction. The translational implications of AM's barrier function have been reviewed comprehensively in Hypertension Research (2022).

Cardiac Research: Hypertrophy, Failure, and Infarction

Cardiac expression of AM is dramatically upregulated in volume overload, pressure overload, myocardial infarction, and heart failure. This upregulation appears to represent an adaptive response, as AM exerts anti-hypertrophic, anti-fibrotic, and anti-apoptotic effects on cardiomyocytes in preclinical models:

• •AM suppresses angiotensin II-induced cardiomyocyte hypertrophy via cAMP/PKA-dependent inhibition of NFAT and ERK signaling
• •In ischemia-reperfusion models, AM pretreatment reduces infarct size and preserves cardiac function through activation of survival kinases (PI3K/Akt, ERK1/2)
• •AM stimulates cardioprotective autophagy in cardiomyocytes during metabolic stress

A detailed review of AM's cardioprotective mechanisms was published in Circulation Research (2024), summarizing the landscape of AM-based cardiovascular research. Earlier work on the cardioprotective spectrum of AM was reviewed in PubMed 29577955.

---

Pulmonary Research

The lung is both the primary site of AM clearance (via pulmonary endothelium) and a major site of synthesis. This dual role positions AM as a critical regulator of pulmonary vascular homeostasis.

Pulmonary Hypertension Research

Pulmonary arterial hypertension (PAH) research has extensively examined adrenomedullin:

• •AM expression is markedly reduced in pulmonary artery smooth muscle cells and endothelial cells in PAH models
• •Loss of AM₁ receptor signaling impairs pulmonary vasodilation and promotes vasoconstriction and remodeling
• •RAMP2-deficient mice develop severe pulmonary hypertension with vascular remodeling and right ventricular dysfunction

These findings establish AM/CLR/RAMP2 as a pathway whose disruption contributes to PAH pathogenesis and whose activation may represent a research target for pulmonary vascular protection. For comparison with other vasoactive peptides studied in pulmonary vascular contexts, see the profiles for Natriuretic Peptides (ANP, BNP, CNP) and Apelin.

Acute Lung Injury Research

In lipopolysaccharide (LPS) models of acute lung injury, AM expression in pulmonary epithelium and endothelium is dramatically upregulated. Exogenous AM administration reduces:

• •Alveolar permeability and protein leak
• •Neutrophil influx and inflammatory cytokine levels (TNF-α, IL-6, IL-1β)
• •Oxidative stress markers in lung tissue

AM deficiency in neonatal mice potentiates LPS-induced bronchopulmonary dysplasia, establishing AM as a developmental lung-protective factor (PubMed 34508690).

---

Neuroendocrine and CNS Research

Neuroprotection in Ischemia

AM is produced by cerebrovascular endothelial cells, astrocytes, and neurons, and its expression is upregulated following ischemic injury. Research in rodent stroke models has demonstrated:

• •AM reduces infarct volume following middle cerebral artery occlusion
• •Neuroprotective mechanisms include suppression of oxidative stress, reduction of caspase-3 activation, and preservation of blood-brain barrier integrity
• •AM promotes post-stroke angiogenesis in the ischemic penumbra, potentially supporting neurological recovery

A comprehensive review of AM's neuroprotective properties characterized its potential as "exciting new horizons" for cerebrovascular disease research (PubMed 22216776).

Hypothalamic and Neuroendocrine Functions

AM is expressed in hypothalamic nuclei and modulates multiple neuroendocrine axes:

• •HPA axis: AM inhibits ACTH and cortisol secretion at the pituitary level, potentially acting as a counter-regulatory signal during stress (see also ACTH research profile)
• •Vasopressin axis: AM influences ADH secretion and renal water handling
• •Appetite regulation: AM immunoreactivity in hypothalamic nuclei involved in energy homeostasis suggests a role in satiety signaling, though this remains an active area of investigation

For context on the broader neuropeptide signaling landscape, see the profiles for PACAP and Neurotensin, both of which share hypothalamic distribution and pleiotropic neuroendocrine activities with AM.

---

Tumor Biology Research

Adrenomedullin's role in cancer biology is complex and context-dependent. It can promote tumor growth and angiogenesis in established tumors while simultaneously representing a compelling anti-tumor research target.

Pro-Tumor Mechanisms

Multiple tumor types — including glioblastoma, breast, ovarian, colorectal, cervical, and renal cell carcinoma — overexpress AM. Within the tumor microenvironment, AM:

• •Promotes tumor angiogenesis: AM produced by tumor cells and tumor-associated macrophages (TAMs) signals through AM₁/AM₂ receptors on tumor endothelial cells, driving neo-vascularization necessary for tumor growth. TAM-derived AM promotes angiogenesis in both autocrine and paracrine fashions in melanoma models (PubMed 21994414)
• •Suppresses apoptosis: AM activates PI3K/Akt survival signaling in tumor cells and tumor endothelium, reducing sensitivity to apoptotic stimuli
• •Supports hypoxic adaptation: HIF-1α, the master transcriptional regulator of the hypoxic response, directly induces AM transcription, creating a feed-forward loop that sustains tumor vascularization under hypoxia
• •Promotes immune evasion: AM signaling on tumor-infiltrating macrophages may skew polarization toward a pro-tumor M2 phenotype
• •Facilitates metastasis: AM promotes epithelial-mesenchymal transition (EMT) and matrix metalloproteinase activity in some tumor cell lines

A comprehensive review of AM's roles across tumorigenesis stages was published in PMC 12193685.

Anti-AM Research Strategies

The recognition of AM as a pro-tumor factor has motivated research into anti-AM approaches:

• •Neutralizing antibodies: Systemic delivery of anti-AM antibodies significantly suppressed tumor angiogenesis and xenograft tumor growth in mice by disrupting tumor endothelial cell function (PubMed 19546305)
• •AM receptor antagonists: Small molecule and peptide-based antagonists of AM receptors have shown anti-angiogenic activity in renal cell carcinoma models, selectively targeting tumor endothelial cells without apparent effects on normal vasculature (PubMed 20428760)
• •mRNA vaccine approach: A 2024 study demonstrated that a KLH-AM mRNA vaccine eliciting humoral and cellular immunity against AM reduced angiogenesis and delayed tumor growth in a subcutaneous melanoma model without inducing an immunosuppressive tumor microenvironment (PubMed 41226782), representing a novel immunological approach to AM targeting

---

Sepsis and Inflammatory Disease Research

MR-proADM as a Sepsis Biomarker

Perhaps the most translatable adrenomedullin research has focused on mid-regional proadrenomedullin (MR-proADM) as a biomarker for sepsis severity and outcome. Because native AM has a short half-life, MR-proADM — a stable fragment of the AM precursor — is the preferred measurable surrogate. Key findings:

• •Plasma MR-proADM levels rise dramatically in sepsis and correlate with the degree of cardiovascular compromise, organ dysfunction, and mortality risk
• •MR-proADM outperforms traditional biomarkers (CRP, PCT) in predicting 28-day mortality in sepsis patients (PubMed 30207133)
• •In combination with clinical scores, MR-proADM improves risk stratification for ICU admission and escalation of care

COVID-19 Severity and Endothelial Research

The endothelial-injury paradigm of severe COVID-19 brought adrenomedullin into sharp research focus:

• •MR-proADM levels at hospital admission accurately predict development of ARDS and severe respiratory failure in COVID-19 patients, independent of traditional risk factors
• •Bio-ADM levels correlate with later development of multi-organ failure in critically ill COVID-19 patients
• •A systematic review of MR-proADM in COVID-19 ICU management examined 12 studies spanning 2020-2022, confirming its value as a severity stratification biomarker (PubMed 35956159)
• •Effectiveness of MR-proADM vs. lymphocyte subpopulations and immunoglobulins in COVID-19 prognosis was assessed in a 15-month prospective observational study (PubMed 37035317)

---

Renal and Metabolic Research

Renal Hemodynamics and Electrolyte Handling

AM exerts direct effects on kidney function relevant to renal physiology research:

• •Increases renal plasma flow and glomerular filtration rate via afferent arteriolar vasodilation
• •Promotes natriuresis and diuresis, counterbalancing the actions of aldosterone and vasopressin
• •AM₁ receptor expression on tubular cells mediates anti-inflammatory and anti-fibrotic effects, with potential relevance to chronic kidney disease research models

Metabolic Connections

Emerging research implicates AM in insulin sensitivity and adipose biology:

• •AM promotes glucose uptake in skeletal muscle through PI3K/Akt-dependent mechanisms independent of the insulin receptor
• •AM is expressed in adipocytes and may regulate adipogenesis and lipid metabolism, connecting it to broader metabolic research programs that include GLP-1 agonists, Adiponectin, and Leptin

---

Adrenomedullin Research Tools and Assays

Research with adrenomedullin employs a variety of molecular tools:

---

Key Research Findings Summary

---

Research Limitations and Outstanding Questions

Despite three decades of AM research, several fundamental questions remain open:

1. Receptor subtype biology: The precise functional differences between AM₁ and AM₂ receptors in vivo remain incompletely characterized; developing truly AM₂-selective tools is an ongoing challenge in chemical biology

2. Biased agonism: Whether it is possible to develop AM analogs with selective activation of protective (barrier-enhancing, anti-fibrotic) vs. potentially detrimental (pro-angiogenic in tumors) signaling arms remains pharmacologically open

3. Half-life challenge: Native AM's short half-life (≈22 min) limits its utility as a research tool for sustained receptor activation; development of stable AM analogs with extended pharmacokinetics is an active area

4. Tumor biology paradox: AM appears pro-tumorigenic in established tumors through angiogenesis promotion, yet some data suggest anti-proliferative activity in specific tumor contexts; the determinants of this switch are not fully understood

5. Adrenomedullin 2/Intermedin: The related peptide adrenomedullin 2 (AM2, also called intermedin) shares receptor biology and overlapping functions; dissecting AM vs. AM2 contributions in biological systems requires careful experimental design and selective tools

---

Summary

Adrenomedullin is a 52-amino-acid peptide of the calcitonin superfamily that operates through heterodimeric CLR/RAMP2 (AM₁) and CLR/RAMP3 (AM₂) receptor complexes to exert pleiotropic effects across cardiovascular, pulmonary, neuroendocrine, renal, and tumor biology systems. Its potent vasodilatory and endothelial barrier-protective properties make it a focus of cardiovascular and sepsis research; its obligate role in tumor angiogenesis makes it a compelling anti-tumor research target; and its MR-proADM surrogate has emerged as a clinically validated biomarker for sepsis and COVID-19 severity risk stratification.

The complexity of AM's receptor pharmacology — with distinct AM₁ and AM₂ receptor subtypes mediating biased signaling through different RAMP partners — ensures that receptor-subtype-specific research tools will be critical for future mechanistic studies. As the field moves toward developing stable AM analogs with improved pharmacokinetics and RAMP-selective compounds, adrenomedullin is poised to remain a productive focus for research across multiple disease-relevant biology domains.

---

All adrenomedullin research compounds described herein are intended exclusively for laboratory investigation under Research Use Only (RUO) conditions. This content does not constitute medical advice, clinical guidance, or endorsement for human or animal use.